-
平臺編號：bio-131652
-
細(xì)胞信息： USPC-ARK-1
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
人子宮內(nèi)膜癌細(xì)胞USPC-ARK-1
細(xì)胞名稱：人子宮內(nèi)膜癌細(xì)胞USPC-ARK-1
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研2類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人子宮內(nèi)膜癌細(xì)胞USPC-ARK-1取自62歲女性供體，貼壁培養(yǎng)。
注釋：Endometrial serous adenocarcinoma
基因突變：PIK3CA p.Glu542Lys(c.1624G>A)(PubMed=23891627;PubMed=26325104).
HLA信息：/
STR信息：/
參考文獻(xiàn)
PubMed=19920829;DOI=10.1038/sj.bjc.6605448
El-Sahwi K.,Bellone S.,Cocco E.,Cargnelutti M.,Casagrande F.,Bellone M.,Abu-Khalaf M.,Buza N.,Tavassoli F.A.,Hui P.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
Br.J.Cancer 102:134-143(2010)
PubMed=21246534;DOI=10.1002/cncr.25891
Varughese J.,Cocco E.,Bellone S.,de Leon M.,Bellone M.,Todeschini P.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker(Trop-2)and are highly sensitive to immunotherapy with hRS7,a humanized anti-Trop-2 monoclonal antibody.
Cancer 117:3163-3172(2011)
PubMed=23891627;DOI=10.1016/j.ajog.2013.07.020
English D.P.,Bellone S.,Cocco E.,Bortolomai I.,Pecorelli S.,Lopez S.,Silasi D.-A.,Schwartz P.E.,Rutherford T.,Santin A.D.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980,a selective inhibitor of Class I PI3 kinase and mTOR kinase(TORC1/2).
Am.J.Obstet.Gynecol.209:465.e1-465.e9(2013)
PubMed=26325104;DOI=10.1038/bjc.2015.306
Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br.J.Cancer 113:1020-1026(2015)
PubMed=26625219;DOI=10.1038/bjc.2015.388
Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.
Erratum to:PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br.J.Cancer 113:1641-1641(2015)
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研2類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人子宮內(nèi)膜癌細(xì)胞USPC-ARK-1取自62歲女性供體，貼壁培養(yǎng)。
注釋：Endometrial serous adenocarcinoma
基因突變：PIK3CA p.Glu542Lys(c.1624G>A)(PubMed=23891627;PubMed=26325104).
HLA信息：/
STR信息：/
參考文獻(xiàn)
PubMed=19920829;DOI=10.1038/sj.bjc.6605448
El-Sahwi K.,Bellone S.,Cocco E.,Cargnelutti M.,Casagrande F.,Bellone M.,Abu-Khalaf M.,Buza N.,Tavassoli F.A.,Hui P.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
Br.J.Cancer 102:134-143(2010)
PubMed=21246534;DOI=10.1002/cncr.25891
Varughese J.,Cocco E.,Bellone S.,de Leon M.,Bellone M.,Todeschini P.,Schwartz P.E.,Rutherford T.J.,Pecorelli S.,Santin A.D.
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker(Trop-2)and are highly sensitive to immunotherapy with hRS7,a humanized anti-Trop-2 monoclonal antibody.
Cancer 117:3163-3172(2011)
PubMed=23891627;DOI=10.1016/j.ajog.2013.07.020
English D.P.,Bellone S.,Cocco E.,Bortolomai I.,Pecorelli S.,Lopez S.,Silasi D.-A.,Schwartz P.E.,Rutherford T.,Santin A.D.
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980,a selective inhibitor of Class I PI3 kinase and mTOR kinase(TORC1/2).
Am.J.Obstet.Gynecol.209:465.e1-465.e9(2013)
PubMed=26325104;DOI=10.1038/bjc.2015.306
Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br.J.Cancer 113:1020-1026(2015)
PubMed=26625219;DOI=10.1038/bjc.2015.388
Black J.D.,Lopez S.,Cocco E.,Bellone S.,Altwerger G.,Schwab C.L.,English D.P.,Bonazzoli E.,Predolini F.,Ferrari F.,Ratner E.,Silasi D.-A.,Azodi M.,Schwartz P.E.,Santin A.D.
Erratum to:PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br.J.Cancer 113:1641-1641(2015)
